Secondary angiosarcoma following catheter‐based brachytherapy

2020 ◽  
Author(s):  
Christa R. Balanoff ◽  
Kelsey E. Larson ◽  
Leigh Anna Robinson ◽  
Jamie L. Wagner ◽  
Amanda L. Amin
Keyword(s):  
Secondary Angiosarcoma

Magnetic resonance imaging appearances in primary and secondary angiosarcoma of the breast

2013 ◽  
Vol 58 (2) ◽  
pp. 208-212 ◽  
Author(s):  
Ailbhe C O'Neill ◽  
Clare D'Arcy ◽  
Enda McDermott ◽  
Ann O'Doherty ◽  
Cecily Quinn ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Resonance Imaging ◽  
Angiosarcoma Of The Breast ◽  
Secondary Angiosarcoma

scholarly journals Optimal Clinical Management and the Molecular Biology of Angiosarcomas

Cancers ◽  
2020 ◽  
Vol 12 (11) ◽  
pp. 3321
Author(s):  
Tom Wei-Wu Chen ◽  
Jessica Burns ◽  
Robin L. Jones ◽  
Paul H. Huang
Keyword(s):  
Clinical Management ◽  
Standard Treatment ◽  
Checkpoint Inhibitors ◽  
Soft Tissue Sarcomas ◽  
Phase 3 ◽  
Molecular Alterations ◽  
Molecular Features ◽  
Different Origins ◽  
Chronic Lymphedema ◽  
Secondary Angiosarcoma

Angiosarcomas comprise less than 3% of all soft tissue sarcomas but have a poor prognosis. Most angiosarcomas occur without obvious risk factors but secondary angiosarcoma could arise after radiotherapy or chronic lymphedema. Surgery remains the standard treatment for localized angiosarcoma but neoadjuvant systemic treatment may improve the curability. For advanced angiosarcoma, anthracyclines and taxanes are the main chemotherapy options. Anti-angiogenic agents have a substantial role but the failure of a randomized phase 3 trial of pazopanib with or without an anti-endoglin antibody brings a challenge to future trials in angiosarcomas. Immune checkpoint inhibitors as single agents or in combination with oncolytic virus may play an important role but the optimal duration remains to be investigated. We also report the current understanding of the molecular pathways involved in angiosarcoma pathogenesis including MYC amplification, activation of angiogenic pathways and different molecular alterations that are associated with angiosarcomas of different aetiology. The success of the patient-partnered Angiosarcoma Project (ASCProject) has provided not only detailed insights into the molecular features of angiosarcomas of different origins but also offers a template for future fruitful collaborations between patients, physicians, and researchers. Lastly, we provide our perspective of future developments in optimizing the clinical management of angiosarcomas.

Abstract 756: Whole exome sequencing identifies frequent mutations of PTPRB and KDR in secondary angiosarcoma

2019 ◽  
Author(s):  
Tenzin Gayden ◽  
Brendan C. Dickson ◽  
Hamid Nikbakht ◽  
Pierre-Olivier Fiset ◽  
Nicolas De Jay ◽  
...  
Keyword(s):  
Exome Sequencing ◽  
Whole Exome Sequencing ◽  
Whole Exome ◽  
Frequent Mutations ◽  
Secondary Angiosarcoma

Secondary Angiosarcoma With C-MYC Amplification Following Prophylactic Bilateral Mastectomy and Autologous Breast Reconstruction: Report of a Case and Review of the Literature

2020 ◽  
pp. 106689692093010
Author(s):  
Chrisopher Webb ◽  
Natalia Partain ◽  
Prasad Koduru ◽  
Helena Hwang ◽  
Venetia R. Sarode
Keyword(s):  
Breast Cancer ◽  
Brca1 Gene ◽  
Tumor Infiltrating Lymphocytes ◽  
Lymphatic Drainage ◽  
Bilateral Mastectomy ◽  
Prior History ◽  
Autologous Reconstruction ◽  
Variant Of Uncertain Significance ◽  
History Of ◽  
Secondary Angiosarcoma

In this article, we report a very rare case of secondary angiosarcoma in a young woman with no prior history of breast cancer who had bilateral prophylactic mastectomies with autologous reconstruction due to a strong family history of breast cancer and BRCA1 gene variant of uncertain significance. The surgery was complicated by recurrent fat necrosis requiring several excisions and additional reconstruction followed by the development of localized lymphedema and subsequent angiosarcoma in the reconstructed breast 10 years later. The angiosarcoma was high grade with prominent epithelioid features associated with abundant tumor-infiltrating lymphocytes. Amplification of C-MYC locus 8q21.24 was demonstrated by fluorescence in situ hybridization study. We postulate that chronic trauma from several surgeries including tissue hypoxia and impaired lymphatic drainage may have provided a milieu for angiogenesis and mutagenic transformation. Amplification of C-MYC locus 8q21.24 was most likely a strong oncogenic driver of angiosarcoma. To the best of our knowledge, this is the first report of its kind in the literature.

Primary and secondary angiosarcoma of the breast: The Mayo Clinic experience

2010 ◽  
Vol 101 (5) ◽  
pp. 401-407 ◽  
Author(s):  
Jeffrey S. Scow ◽  
Carol A. Reynolds ◽  
Amy C. Degnim ◽  
Ivy A. Petersen ◽  
James W. Jakub ◽  
...  
Keyword(s):  
Mayo Clinic ◽  
Angiosarcoma Of The Breast ◽  
Clinic Experience ◽  
Secondary Angiosarcoma

Recurrence of secondary angiosarcoma in a patient with post-radiated breast for breast cancer

2008 ◽  
Vol 278 (5) ◽  
pp. 497-501 ◽  
Author(s):  
Thomas Kunkel ◽  
Ioannis Mylonas ◽  
Doris Mayr ◽  
Klaus Friese ◽  
Harald L. Sommer
Keyword(s):  
Breast Cancer ◽  
Secondary Angiosarcoma

FISH for MYC amplification and anti-MYC immunohistochemistry: useful diagnostic tools in the assessment of secondary angiosarcoma and atypical vascular proliferations

2011 ◽  
Vol 39 (2) ◽  
pp. 234-242 ◽  
Author(s):  
Anthony P. Fernandez ◽  
Yang Sun ◽  
Raymond R. Tubbs ◽  
John R. Goldblum ◽  
Steven D. Billings
Keyword(s):  
Diagnostic Tools ◽  
Secondary Angiosarcoma
Sign in / Sign up

Export Citation Format

Share Document